Intravitreal Injection of AAV Expressing Soluble VEGF Receptor-1 Variant Induces Anti-VEGF Activity and Suppresses Choroidal Neovascularization | Zendy

Steven Hyun Seung Lee | Zendy; Hee Jong Kim | Zendy; Oh Kyu Shin | Zendy; JunSub Choi | Zendy; Jin Kim | Zendy; Young-Hwa Cho | Zendy; Joohun Ha | Zendy; Tae Kwann Park | Zendy; Joo Yong Lee | Zendy; Keerang Park | Zendy; Heuiran Lee | Zendy

Open Access

Intravitreal Injection of AAV Expressing Soluble VEGF Receptor-1 Variant Induces Anti-VEGF Activity and Suppresses Choroidal Neovascularization

Author(s) -

Steven Hyun Seung Lee,

Hee Jong Kim,

Oh Kyu Shin,

JunSub Choi,

Jin Kim,

Young-Hwa Cho,

Joohun Ha,

Tae Kwann Park,

Joo Yong Lee,

Keerang Park,

Heuiran Lee

Publication year - 2018

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.18-24926

Subject(s) - choroidal neovascularization , bevacizumab , medicine , cytokeratin , intravitreal administration , cd31 , pathology , cancer research , vascular endothelial growth factor , immunostaining , neovascularization , ophthalmology , retinal , angiogenesis , chemotherapy , immunohistochemistry , surgery , vegf receptors

With anti-VEGF-based treatments for wet AMD requiring frequent injections, it is often burdensome to both patients and healthcare providers. To explore its possibility as a desirable alternative, we investigated the therapeutic potential of a recombinant adeno-associated virus 2 expressing a soluble variant of VEGF receptor-1 (rAAV2-sVEGFRv-1) in a laser-induced choroidal neovascularization (CNV) model, as CNV is a defining feature of AMD progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research